Related Experiment Videos
Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys
Abstract:
The metabolic disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine (2-F-AraA) has been studied in mice, dogs, and monkeys after iv administration. Following injection of 2-F-AraA (30 mg/m2) into mice, serum levels fell with apparent half-lives of 17 min for the alpha-phase and 72 min for the beta-phase. For dogs given the same dose, these values were less than 5 and 112 min, and, for monkeys, 26 and 125 min, respectively. A higher concentration of metabolites was present in the serum of dogs than in the serum of mice and monkeys. Phosphorylated derivatives of 2-F-AraA were present in each of several mouse tissues examined; liver contained the highest concentration. In 24 hr, mice excreted more than half of the administered compound in the urine as unchanged 2-F-AraA. For dogs given a dose of 400 mg/m2, a single phase of disappearance of the drug (t1/2 = 130 min) was observed. For a single monkey, there were two phases, with half-lives of 15 min and 6.7 hr. In the urine, monkeys excreted about half of either dose as parent compound; but dogs excreted only about one-fourth as unchanged drug. These data indicate that 2-F-AraA is extensively metabolized by dogs but less so by mice and monkeys.
Insights
The study investigated the metabolic fate of 9-beta-D-arabinofuranosyl-2-fluoroadenine (2-F-AraA) in mice, dogs, and monkeys. Dogs extensively metabolize 2-F-AraA, unlike mice and monkeys, indicating species-specific drug disposition.
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Comparative Toxicology
Background:
- 9-beta-D-arabinofuranosyl-2-fluoroadenine (2-F-AraA) is an antiviral agent.
- Understanding its metabolic disposition is crucial for therapeutic applications.
- Species-specific differences in drug metabolism can impact efficacy and safety.
Purpose of the Study:
- To characterize the metabolic disposition of 2-F-AraA in different animal models.
- To compare the pharmacokinetic profiles and metabolic pathways of 2-F-AraA across species.
- To identify potential factors influencing 2-F-AraA's efficacy and safety.
Main Methods:
- Intravenous administration of 2-F-AraA to mice, dogs, and monkeys.
- Serum level monitoring and pharmacokinetic analysis (half-life determination).
- Analysis of urinary excretion and tissue distribution of 2-F-AraA and its metabolites.
Main Results:
- 2-F-AraA exhibited distinct pharmacokinetic profiles across species, with shorter half-lives in mice and dogs compared to monkeys.
- Dogs showed a higher concentration of metabolites in serum, indicating extensive metabolism.
- Mice excreted a significant portion as unchanged 2-F-AraA, while dogs excreted less unchanged drug, suggesting species-specific metabolic pathways.
Conclusions:
- Dogs extensively metabolize 2-F-AraA, whereas mice and monkeys exhibit less extensive metabolism.
- Species-specific metabolic differences in 2-F-AraA disposition are significant.
- These findings have implications for the development and clinical use of 2-F-AraA.